# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19

> **NCT05216601** · PHASE1 · COMPLETED · sponsor: **Medigen Vaccine Biologics Corp.** · enrollment: 107 (actual)

## Conditions studied

- COVID-19 Vaccine

## Interventions

- **BIOLOGICAL:** MVC-COV1901
- **BIOLOGICAL:** MVC-COV1901(Beta)-15
- **BIOLOGICAL:** MVC-COV1901(Beta)-25

## Key facts

- **NCT ID:** NCT05216601
- **Lead sponsor:** Medigen Vaccine Biologics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-06
- **Primary completion:** 2022-07-26
- **Final completion:** 2022-11-30
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2023-03-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05216601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05216601, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901 or MVC-COV1901(Beta) Against COVID-19". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05216601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*